Skip to content

VIDAS® Lyme IgM II 416436Recalls & reported problems

Biomerieux SA · VIDAS Lyme IgM II assay is an automated qualitative enzyme immunoassay intended for use on VIDAS family instrument for detection of human IgM antibodies to Borrelia burgdorferi. · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
2
Deaths reported
0
Injuries reported
0
Recalls naming it
1

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 03573026447151), received between Dec 1, 2017 and Jan 31, 2020 — classified as 2 malfunctions.

The most frequently reported specific device problem is “False Negative Result” (1 report).

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Recalls naming this device

  1. Sep 22, 2021Class IIOpen, Classified

    bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.

    Z-0436-2022 · Root cause: Nonconforming Material/Component · Recall details · FDA record ↗

Most reported problems

Device problems

  • False Negative Result1
  • Incorrect, Inadequate or Imprecise Result or Readings1

Patient problems

  • No Known Impact Or Consequence To Patient2

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJan 31, 2020Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

    A CUSTOMER IN THE UNITED STATES NOTIFIED BIOMÉRIEUX OF OBTAINING A FALSE NEGATIVE RESULT FOR PATIENT SAMPLE IN ASSOCIATION WITH THE VIDAS® LYME IGM 60 TESTS (REF 416436, LOT NUMBER NOT SPECIFIED). THE CUSTOMER TESTED THE PATIENT SAMPLE USING VIDAS® LYME IGM 60 TESTS WHICH OBTAINED A NEGATIVE RESULT. THE CUSTOMER ALSO TESTED THE SAMPLE USING WESTERN BLOT AND SOFIA TEST METHOD, BOTH ASSAYS YIELDED A POSITIVE RESULT. THERE IS NO INDICATION OR REPORT FROM THE LABORATORY THAT THE DISCREPANT RESULT LED TO ANY ADVERSE EVENT RELATED TO THE PATIENT'S STATE OF HEALTH. BIOMÉRIEUX WILL INITIATE AN INTERNAL INVESTIGATION.

    Patient problems: No Known Impact Or Consequence To Patient

    MAUDE report 9652884 ↗
  • MalfunctionDec 1, 2017False Negative Result; False Negative Result

    A CUSTOMER FROM THE UNITED STATES NOTIFIED BIOMÉRIEUX OF FALSE NEGATIVE RESULTS ASSOCIATED WITH THE VIDAS® LYME IGM INVOLVING A PATIENT SAMPLE. THE CUSTOMER INDICATED RUNNING THE PATIENT SAMPLE AND GETTING NEGATIVE RESULT; HOWEVER, THE SAMPLE WAS SENT TO A REFERENCE LAB WHERE THE WESTERN BLOT WAS POSITIVE FOR MULTIPLE BANDS. THE CUSTOMER REPORTED THE SPECIMEN THEY TESTED AND THE SPECIMEN THE REFERENCE LAB TESTED WERE OBTAINED FROM THE PATIENT AT THE SAME TIME BUT WERE IN DIFFERENT TUBES. SERUM WAS USED FOR BOTH TESTS. THE CUSTOMER INDICATED NEITHER SPECIMEN IS AVAILABLE FOR SUBMISSION TO BIOMÉRIEUX.. A BIOMÉRIEUX INVESTIGATION WILL BE INITIATED.

    Patient problems: No Known Impact Or Consequence To Patient

    MAUDE report 7076035 ↗

Other Reagent, Borrelia Serological Reagent devices

All Reagent, Borrelia Serological Reagent devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page